| Source Date | Board Meeting Date | Details |
|
17-Oct-2025
|
13-Nov-2025
|
Quarterly Results
|
|
24-Jul-2025
|
11-Aug-2025
|
Quarterly Results
|
|
14-May-2025
|
29-May-2025
|
Audited Results & Final Dividend
|
|
27-Jan-2025
|
13-Feb-2025
|
Quarterly Results
|
|
24-Oct-2024
|
14-Nov-2024
|
Quarterly Results & Interim Dividend
|
|
23-Sep-2024
|
30-Sep-2024
|
Inter alia, to consider and approve:- (1) Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company?s subsidiary)
|
|
24-Jul-2024
|
13-Aug-2024
|
Quarterly Results
|
|
07-May-2024
|
29-May-2024
|
Final Dividend & Audited Results
|
|
23-Jan-2024
|
14-Feb-2024
|
Quarterly Results
|
|
25-Oct-2023
|
10-Nov-2023
|
Quarterly Results & Interim Dividend
|
|
21-Jul-2023
|
10-Aug-2023
|
Quarterly Results
|
|
12-May-2023
|
29-May-2023
|
Audited Results
|
|
20-Jan-2023
|
14-Feb-2023
|
Quarterly Results
|
|
02-Nov-2022
|
11-Nov-2022
|
Quarterly Results & Interim Dividend
|
|
28-Jul-2022
|
10-Aug-2022
|
Quarterly Results
|
|
12-May-2022
|
24-May-2022
|
Audited Results & Amalgamation
|
|
31-Jan-2022
|
14-Feb-2022
|
Quarterly Results
|
|
20-Oct-2021
|
13-Nov-2021
|
Interim Dividend & Stock Split & Quarterly Results
|
|
22-Jul-2021
|
05-Aug-2021
|
Quarterly Results
|
|
17-May-2021
|
28-May-2021
|
Audited Results
|